AVITA Medical, Inc. (RCEL)

Market Cap	256.99M
Revenue (ttm)	64.25M
Net Income (ttm)	-61.85M
Shares Out	26.36M
EPS (ttm)	-2.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	259,660
Open	10.22
Previous Close	9.95
Day's Range	9.53 - 10.40
52-Week Range	7.51 - 18.93
Beta	1.55
Analysts	Buy
Price Target	17.25 (+76.92%)
Earnings Date	Feb 13, 2025

About RCEL

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting devi...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: James Corbett
• Employees: 207
• Stock Exchange: NASDAQ
• Ticker Symbol: RCEL
• Website: https://avitamedical.com

Financial Performance

In 2024, AVITA Medical's revenue was $64.25 million, an increase of 28.14% compared to the previous year's $50.14 million. Losses were -$61.85 million, 74.8% more than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for RCEL stock is "Buy." The 12-month stock price forecast is $17.25, which is an increase of 76.92% from the latest price.

Price Target

$17.25

(76.92% upside)

Analyst Consensus: Buy